Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.…
Century Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
Century Therapeutics (NASDAQ: IPSC) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 78 employees.
The shares were at 1.165 USD on 20 November 2026, up 117.8% over 52 weeks. Its 52-week range is 0.4350 USD to 3.040 USD: the price is 61.7% below the high and 167.8% above the low.
Its market capitalisation is 211.56M USD.
Century Therapeutics reports return on equity of -6.0% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 79.71M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 11 March 2027.